NipentExtra

Drug Profile

NipentExtra

Alternative Names: PentoExtra; Pentostatin - SuperGen

Latest Information Update: 16 Nov 2006

Price : $50

At a glance

  • Originator SuperGen
  • Class
  • Mechanism of Action Adenosine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hairy cell leukaemia

Most Recent Events

  • 25 Jan 1999 PentoExtra is now called NipentExtra
  • 08 May 1998 Preclinical development for Hairy cell leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top